Top

Published in:

Open Access 01-06-2020 | Acute Myeloid Leukemia | Original Article

Enumeration of CD34+ blasts by immunohistochemistry in bone marrow biopsies from MDS patients may have significant impact on final WHO classification

Authors: Leonie Saft, Botond Timar, Anna Porwit

Published in: Journal of Hematopathology | Issue 2/2020

Abstract

The percentage of blasts cells in the bone marrow (BM) of MDS patients is one of the key parameters for MDS classification and for the differential diagnosis with acute myeloid leukemia (AML). Currently, the gold standard to determine the blast percentage is conventional cytomorphology. To assess the possible impact of blast cell enumeration in BM biopsies from MDS patients on the final WHO classification using CD34 immunohistochemistry (IHC) a total of 156 BM samples from MDS and MDS-AML patients were studied and compared to blast counts by cytomorphology (CM). Eighty-nine BM aspirates were also studied by flow cytometry (FCM). Percentages of CD34+ blasts by IHC were determined blindly by two hematopathologists. Automated CD34-cell count was performed in 25 cases. Good overall agreement was found for CM and FCM with respect to critical blast thresholds (5%, 10%, 20%) (p < 0.05). However, in 17% of patients, CD34+ blast counts by IHC were higher as compared to CM with possible impact on MDS subclassification. In 7 of 21 AML patients, diagnosis was established on BM histology, while the blast percentage by CM was below the AML threshold. The assessment of CD34+ cells by IHC showed high interobserver agreement (Spearman R 0.95, p < 0.01), while automated CD34 counts were not optimal due to interference with other cellular and stromal elements. BM histology including CD34 IHC improves the diagnostic accuracy in MDS and AML. The quantification of blast cells should be based on the integration of all three methods for reliable disease classification and risk assessment.

Available only for authorised users

Swerdlow SH, World Health Organization, International Agency for Research on Cancer (2017) WHO classification of tumours of haematopoietic and lymphoid tissues. World Health Organization classification of tumours, Revised 4th edition. edn.

Cazzola M, Malcovati L (2010) Prognostic classification and risk assessment in myelodysplastic syndromes. Hematol Oncol Clin North Am 24(2):459–468CrossRefPubMed

Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89(6):2079–2088CrossRefPubMed

Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstocker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120(12):2454–2465CrossRefPubMedPubMedCentral

Mufti GJ, Bennett JM, Goasguen J, Bain BJ, Baumann I, Brunning R, Cazzola M, Fenaux P, Germing U, Hellstrom-Lindberg E, Jinnai I, Manabe A, Matsuda A, Niemeyer CM, Sanz G, Tomonaga M, Vallespi T, Yoshimi A (2008) Diagnosis and classification of myelodysplastic syndrome: international working group on morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica 93(11):1712–1717CrossRefPubMed

Font P, Loscertales J, Soto C, Ricard P, Novas CM, Martin-Clavero E, Lopez-Rubio M, Garcia-Alonso L, Callejas M, Bermejo A, Benavente C, Ballesteros M, Cedena T, Calbacho M, Urbina R, Villarrubia J, Gil S, Bellon JM, Diez-Martin JL, Villegas A (2015) Interobserver variance in myelodysplastic syndromes with less than 5% bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2% blasts. Ann. Hematol. 94(4):565–573. https://doi.org/10.1007/s00277-014-2252-4 CrossRefPubMed

Howe RB, Porwit-MacDonald A, Wanat R, Tehranchi R, Hellstrom-Lindberg E (2004) The WHO classification of MDS does make a difference. Blood 103(9):3265–3270. https://doi.org/10.1182/blood-2003-06-2124 CrossRefPubMed

Senent L, Arenillas L, Luno E, Ruiz JC, Sanz G, Florensa L (2013) Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes. Haematologica 98(4):568–575. https://doi.org/10.3324/haematol.2012.071449 CrossRefPubMedPubMedCentral

Huang TC, Ko BS, Tang JL, Hsu C, Chen CY, Tsay W, Huang SY, Yao M, Chen YC, Shen MC, Wang CH, Tien HF (2008) Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypercellular MDS by international prognostic scoring system, cytogenetic and genetic studies. Leukemia 22(3):544–550. https://doi.org/10.1038/sj.leu.2405076 CrossRefPubMed

10.

Lambertenghi-Deliliers G, Orazi A, Luksch R, Annaloro C, Soligo D (1991) Myelodysplastic syndrome with increased marrow fibrosis: a distinct clinico-pathological entity. Br. J. Haematol. 78(2):161–166CrossRefPubMed

11.

Orazi A, Czader MB (2009) Myelodysplastic syndromes. Am. J. Clin. Pathol. 132(2):290–305. https://doi.org/10.1309/AJCPRCXX4R0YHKWV CrossRefPubMed

12.

Fu B, Jaso JM, Sargent RL, Goswami M, Verstovsek S, Medeiros LJ, Wang SA (2014) Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems. Mod Pathol 27(5):681–689. https://doi.org/10.1038/modpathol.2013.187 CrossRefPubMed

13.

Della Porta MG, Malcovati L, Boveri E, Travaglino E, Pietra D, Pascutto C, Passamonti F, Invernizzi R, Castello A, Magrini U, Lazzarino M, Cazzola M (2009) Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol 27(5):754–762CrossRefPubMed

14.

Xiong B, Nie Y, Tang Z, Xue M, Zuo X (2017) Prognostic evaluation of ALIP and CD34 immunostaining in IPSS-R subgroups of myelodysplastic syndromes. Pathology 49(5):526–533. https://doi.org/10.1016/j.pathol.2017.05.001 CrossRefPubMed

15.

Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, Cermak J, Del Canizo C, Della Porta MG, Fenaux P, Gattermann N, Germing U, Jansen JH, Mittelman M, Mufti G, Platzbecker U, Sanz GF, Selleslag D, Skov-Holm M, Stauder R, Symeonidis A, van de Loosdrecht AA, de Witte T, Cazzola M, European Leukemia N (2013) Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 122(17):2943–2964. https://doi.org/10.1182/blood-2013-03-492884 CrossRefPubMedPubMedCentral

16.

Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–2405. https://doi.org/10.1182/blood-2016-03-643544 CrossRefPubMed

17.

Kern W, Haferlach C, Schnittger S, Haferlach T (2010) Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome: correlation to cytomorphology, cytogenetics, and clinical data. Cancer 116(19):4549–4563CrossRefPubMed

18.

Kern W, Haferlach C, Schnittger S, Alpermann T, Haferlach T (2013) Serial assessment of suspected myelodysplastic syndromes: significance of flow cytometric findings validated by cytomorphology, cytogenetics, and molecular genetics. Haematologica 98(2):201–207. https://doi.org/10.3324/haematol.2012.066787 CrossRefPubMedPubMedCentral

19.

Sandes AF, Kerbauy DM, Matarraz S, Chauffaille Mde L, Lopez A, Orfao A, Yamamoto M (2013) Combined flow cytometric assessment of CD45, HLA-DR, CD34, and CD117 expression is a useful approach for reliable quantification of blast cells in myelodysplastic syndromes. Cytometry B Clin Cytom 84(3):157–166. https://doi.org/10.1002/cyto.b.21087 CrossRefPubMed

20.

Jelic TM, Mellen PF, Zavieh K, Roque JC, Farren SP, Jin B, Ahmad N, Estallila OC, Chang HH (2002) Correlation between the percentages of myeloblasts in bone marrow obtained by flow cytometry and manual counting on glass slide smears in 74 hematologic patients. Leuk Lymphoma 43(10):1927–1931. https://doi.org/10.1080/1042819021000015871 CrossRefPubMed

21.

Wells DA, Benesch M, Loken MR, Vallejo C, Myerson D, Leisenring WM, Deeg HJ (2003) Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 102(1):394–403CrossRefPubMed

22.

Loken MR, van de Loosdrecht A, Ogata K, Orfao A, Wells DA (2008) Flow cytometry in myelodysplastic syndromes: report from a working conference. Leuk Res 32(1):5–17. https://doi.org/10.1016/j.leukres.2007.04.020 CrossRefPubMed

23.

van de Loosdrecht AA, Alhan C, Bene MC, Della Porta MG, Drager AM, Feuillard J, Font P, Germing U, Haase D, Homburg CH, Ireland R, Jansen JH, Kern W, Malcovati L, Te Marvelde JG, Mufti GJ, Ogata K, Orfao A, Ossenkoppele GJ, Porwit A, Preijers FW, Richards SJ, Schuurhuis GJ, Subira D, Valent P, van der Velden VH, Vyas P, Westra AH, de Witte TM, Wells DA, Loken MR, Westers TM (2009) Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica 94(8):1124–1134CrossRefPubMedPubMedCentral

24.

Ogata K, Kishikawa Y, Satoh C, Tamura H, Dan K, Hayashi A (2006) Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes. Blood 108(3):1037–1044. https://doi.org/10.1182/blood-2005-12-4916 CrossRefPubMed

25.

Matarraz S, Lopez A, Barrena S, Fernandez C, Jensen E, Flores-Montero J, Rasillo A, Sayagues JM, Sanchez ML, Barcena P, Hernandez-Rivas JM, Salvador C, Fernandez-Mosteirin N, Giralt M, Perdiguer L, Laranjeira P, Paiva A, Orfao A (2010) Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: a pilot study on a series of 56 patients. Cytometry B Clin Cytom 78(3):154–168. https://doi.org/10.1002/cyto.b.20513 CrossRefPubMed

26.

Font P, Subira D, Matarraz S, Benavente C, Cedena MT, Morado M, Perez Corral A, Bellon JM, Diez-Martin JL (2018) Multicenter comparison of CD34+ myeloid cell count by flow cytometry in low-risk myelodysplastic syndrome. Is it feasible? Cytometry B Clin Cytom 94(3):527–535. https://doi.org/10.1002/cyto.b.21538 CrossRefPubMed

27.

Porwit A, van de Loosdrecht AA, Bettelheim P, Brodersen LE, Burbury K, Cremers E, Della Porta MG, Ireland R, Johansson U, Matarraz S, Ogata K, Orfao A, Preijers F, Psarra K, Subira D, Valent P, van der Velden VH, Wells D, Westers TM, Kern W, Bene MC (2014) Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS. Leukemia 28(9):1793–1798. https://doi.org/10.1038/leu.2014.191 CrossRefPubMed

28.

van de Loosdrecht AA, Westers TM, Ossenkoppele GJ (2008) Flowcytometry in myelodysplastic syndromes: towards a new paradigm in diagnosis and prognostication? LeukRes 32(2):205–207

29.

van de Loosdrecht AA, Ireland R, Kern W, Della Porta MG, Alhan C, Balleisen JS, Bettelheim P, Bowen DT, Burbury K, Eidenschink L, Cazzola M, Chu SS, Cullen M, Cutler JA, Drager AM, Feuillard J, Fenaux P, Font P, Germing U, Haase D, Hellstrom-Lindberg E, Johansson U, Kordasti S, Loken MR, Malcovati L, te Marvelde JG, Matarraz S, Milne T, Moshaver B, Mufti GJ, Nikolova V, Ogata K, Oelschlaegel U, Orfao A, Ossenkoppele GJ, Porwit A, Platzbecker U, Preijers F, Psarra K, Richards SJ, Subira D, Seymour JF, Tindell V, Vallespi T, Valent P, van der Velden VH, Wells DA, de Witte TM, Zettl F, Bene MC, Westers TM (2013) Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an international consortium and the European LeukemiaNet Working Group. Leuk Lymphoma 54(3):472–475. https://doi.org/10.3109/10428194.2012.718341 CrossRefPubMed

30.

Westers TM, Ireland R, Kern W, Alhan C, Balleisen JS, Bettelheim P, Burbury K, Cullen M, Cutler JA, Della Porta MG, Drager AM, Feuillard J, Font P, Germing U, Haase D, Johansson U, Kordasti S, Loken MR, Malcovati L, Te Marvelde JG, Matarraz S, Milne T, Moshaver B, Mufti GJ, Ogata K, Orfao A, Porwit A, Psarra K, Richards SJ, Subira D, Tindell V, Vallespi T, Valent P, van der Velden VH, de Witte TM, Wells DA, Zettl F, Bene MC, van de Loosdrecht AA (2012) Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia 26(7):1730–1741CrossRefPubMed

31.

Della Porta MG, Picone C, Pascutto C, Malcovati L, Tamura H, Handa H, Czader M, Freeman S, Vyas P, Porwit A, Saft L, Westers TM, Alhan C, Cali C, van de Loosdrecht AA, Ogata K (2012) Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study. Haematologica 97(8):1209–1217. https://doi.org/10.3324/haematol.2011.048421 CrossRefPubMedPubMedCentral

32.

Arber DA, Hasserjian RP (2015) Reclassifying myelodysplastic syndromes: what’s where in the new WHO and why. Hematology Am Soc Hematol Educ Program 2015:294–298. https://doi.org/10.1182/asheducation-2015.1.294 CrossRefPubMed

33.

Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A (2005) European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 90(8):1128–1132PubMed

34.

Bjorklund E, Mazur J, Soderhall S, Porwit-MacDonald A (2003) Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia. Leukemia 17(1):138–148CrossRefPubMed

35.

Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, Giagounidis A, Hildebrandt B, Bernasconi P, Knipp S, Strupp C, Lazzarino M, Aul C, Cazzola M (2007) Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25(23):3503–3510CrossRefPubMed

36.

Stetler-Stevenson M, Arthur DC, Jabbour N, Xie XY, Molldrem J, Barrett AJ, Venzon D, Rick ME (2001) Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 98(4):979–987CrossRefPubMed

37.

Bellos F, Kern W (2017) Flow cytometry in the diagnosis of myelodysplastic syndromes and the value of myeloid nuclear differentiation antigen. Cytometry B Clin Cytom 92(3):200–206. https://doi.org/10.1002/cyto.b.21190 CrossRefPubMed

38.

Dunphy CH, O'Malley DP, Perkins SL, Chang CC (2007) Analysis of immunohistochemical markers in bone marrow sections to evaluate for myelodysplastic syndromes and acute myeloid leukemias. Appl Immunohistochem Mol Morphol 15(2):154–159. https://doi.org/10.1097/PAI.0b013e318030dec7 CrossRefPubMed

39.

Dunphy CH, Polski JM, Evans HL, Gardner LJ (2001) Evaluation of bone marrow specimens with acute myelogenous leukemia for CD34, CD15, CD117, and myeloperoxidase. Arch Pathol Lab Med 125(8):1063–1069. https://doi.org/10.1043/0003-9985(2001)125<1063:EOBMSW>2.0.CO;2 CrossRefPubMed

40.

Hanson CA, Ross CW, Schnitzer B (1992) Anti-CD34 immunoperoxidase staining in paraffin sections of acute leukemia: comparison with flow cytometric immunophenotyping. Hum Pathol 23(1):26–32. https://doi.org/10.1016/0046-8177(92)90006-o CrossRefPubMed

41.

Manaloor EJ, Neiman RS, Heilman DK, Albitar M, Casey T, Vattuone T, Kotylo P, Orazi A (2000) Immunohistochemistry can be used to subtype acute myeloid leukemia in routinely processed bone marrow biopsy specimens. Comparison with flow cytometry. Am. J. Clin. Pathol. 113(6):814–822. https://doi.org/10.1309/nalm-440g-4gfy-xpve CrossRefPubMed

42.

Torlakovic EE, Calvo KR, George TI, Hyjek E, Lee SH, Mazur J, Sabattini E, Saft L, Tzankov A, Porwit A (2018) Assessment of CD34-positive blasts in bone marrow core biopsy: inter-observer agreement study. Virchows Arch 473:S4–S4

Title: Enumeration of CD34+ blasts by immunohistochemistry in bone marrow biopsies from MDS patients may have significant impact on final WHO classification
Authors: Leonie Saft
Botond Timar
Anna Porwit
Publication date: 01-06-2020
Publisher: Springer Berlin Heidelberg
Keyword: Acute Myeloid Leukemia
Published in: Journal of Hematopathology / Issue 2/2020
Print ISSN: 1868-9256
Electronic ISSN: 1865-5785
DOI: https://doi.org/10.1007/s12308-020-00394-9

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Enumeration of CD34+ blasts by immunohistochemistry in bone marrow biopsies from MDS patients may have significant impact on final WHO classification

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2020

Histoplasma capsulatum in peripheral blood neutrophils

COVID-19 and remembering Professor Dennis H. Wright

Molecular spectrum and distribution of hemoglobinopathies in southwest of Iran: a seven-year retrospective study

Immunophenotypic and molecular analysis of a B cell lymphoma with discordant light chain expression at different anatomic sites

Does the order of mutational acquisition in myeloproliferative neoplasms matter? Evidence from JAK2 exon 12 and DNMT3A co-mutant polycythemia vera

Peripheral T cell lymphoma, NOS with aberrant αβ and γδ T cell receptor expression in a post-heart transplant patient